Total trials
270
Active
7
Phase 3
27
Total enrollment
764,204
Pipeline matrix
Showing 17 of 17 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Durvalumab | — | — | — | — | 16 | ||
| Bevacizumab | — | — | — | — | 4 | ||
| Tremelimumab | — | — | — | — | 9 | ||
| Oleclumab | — | — | — | — | 6 | ||
| Monalizumab | — | — | — | — | — | 2 | |
| Osimertinib | — | — | — | — | — | 1 | |
| AZD4635 | — | — | — | — | — | 1 | |
| FOLFOX | — | — | — | — | — | 1 | |
| Cetuximab | — | — | — | — | — | 1 | |
| mFOLFOX6 | — | — | — | — | — | 1 | |
| MEDI5752 | — | — | — | — | — | 2 | |
| Carboplatin | — | — | — | — | 3 | ||
| Pemetrexed | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Paclitaxel or Nab-Paclitaxel | — | — | — | — | — | 1 | |
| Axitinib | — | — | — | — | — | 1 | |
| Lenvatinib | — | — | — | — | — | 1 |
Next readouts
- 2016-01-24
- 2020-11-06
- 2021-05-24
- 2021-10-26
- 2022-10-10
- 2025-07-14
- 2025-09-26
Top conditions
- Healthy34
- Influenza33
- Asthma22
- Cancer12
- Advanced Solid Tumors11
- Respiratory Syncytial Virus Infections9
- Type 2 Diabetes Mellitus7
- Rheumatoid Arthritis7
Frequently asked questions about MedImmune LLC
- How many clinical trials does MedImmune LLC have on ClinicalTrials.gov?
- MedImmune LLC is listed as the lead sponsor on 270 clinical trials in ClinicalTrials.gov, 7 of which are currently active (recruiting, enrolling, or ongoing).
- How many of MedImmune LLC's trials are in Phase 3?
- 27 of MedImmune LLC's trials are in Phase 3, spread across 17 active drug programs.
- What therapeutic areas does MedImmune LLC focus on?
- MedImmune LLC's most-studied conditions on ClinicalTrials.gov are Healthy, Influenza, Asthma, Cancer, Advanced Solid Tumors.
- When are MedImmune LLC's next clinical trial readouts?
- MedImmune LLC has 7 upcoming primary-completion readouts tracked here; the soonest is “Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma”, expected around 2016-01-24.